JP2016531910A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531910A5
JP2016531910A5 JP2016534873A JP2016534873A JP2016531910A5 JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5 JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5
Authority
JP
Japan
Prior art keywords
organ
composition
complement inhibitor
complement
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016534873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/051323 external-priority patent/WO2015023972A1/en
Publication of JP2016531910A publication Critical patent/JP2016531910A/ja
Publication of JP2016531910A5 publication Critical patent/JP2016531910A5/ja
Pending legal-status Critical Current

Links

Images

JP2016534873A 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 Pending JP2016531910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361867009P 2013-08-16 2013-08-16
US61/867,009 2013-08-16
PCT/US2014/051323 WO2015023972A1 (en) 2013-08-16 2014-08-15 Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Publications (2)

Publication Number Publication Date
JP2016531910A JP2016531910A (ja) 2016-10-13
JP2016531910A5 true JP2016531910A5 (enExample) 2017-09-28

Family

ID=51494495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534873A Pending JP2016531910A (ja) 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Country Status (5)

Country Link
US (1) US20160184391A1 (enExample)
EP (1) EP3033093A1 (enExample)
JP (1) JP2016531910A (enExample)
CA (1) CA2920293A1 (enExample)
WO (1) WO2015023972A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
JP6618682B2 (ja) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3368073B1 (en) 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
US20190225679A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Tesidolumab for use in the treatment of transplant rejection
CN109310760A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP7570316B2 (ja) * 2018-08-17 2024-10-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 糖鎖抗原除去のための酵素組成物、それに関連する方法、使用、装置およびシステム
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
CN114127560A (zh) * 2019-03-21 2022-03-01 Uab研究基金会 增加细胞对补体介导裂解的敏感性的方法
CA3135367A1 (en) * 2019-04-10 2020-10-15 University Of Massachusetts Factor h vectors and uses thereof
CN110423271A (zh) * 2019-08-07 2019-11-08 北京市农林科学院 鸡cr2基因的克隆、蛋白的表达和纯化及其多克隆抗体的制备
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
WO2022251168A1 (en) * 2021-05-25 2022-12-01 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5723282A (en) 1991-07-08 1998-03-03 The American National Red Cross Method of preparing organs for vitrification
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE69535920D1 (de) 1994-05-20 2009-04-09 Breonics Inc Verfahren zur überwachung der lebensfähigkeit transplantabler organe
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69916807T2 (de) 1998-02-04 2005-01-13 The General Hospital Corp., Boston Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2003061587A2 (en) 2002-01-22 2003-07-31 Genzyme Corporation USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
EP1729583A4 (en) * 2004-03-05 2015-02-25 Turbochef Tech Inc PASS OVEN
CA2566716C (en) 2004-05-14 2014-12-23 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
NZ595305A (en) 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20130323708A1 (en) 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same

Similar Documents

Publication Publication Date Title
JP2016531910A5 (enExample)
Xu et al. Review of current machine perfusion therapeutics for organ preservation
JP6466971B2 (ja) 臓器、組織又は細胞移植用組成物、キット及び移植方法
Patel et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage
JP2016531910A (ja) 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
JP2022088551A (ja) 増殖造血幹細胞／前駆細胞集団の利用
US20220249595A1 (en) Compositions and methods for treating acute radiation syndrome
JP2009514553A5 (enExample)
CA2815237C (en) Method of improving transplant function using soluble complement receptor type i (scr1)
Dangoor et al. Transplantation: a brief history
US20200329698A1 (en) Compositions for organ graft preservation and methods of use
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
Anderson et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
AU773516B2 (en) Organ transplant solutions containing conjugates of soluble peptidic compounds with membrane-binding
JP3543106B2 (ja) 膜結合型ｃ１インアクチベーター
JP6887628B2 (ja) 被移植体における移植不全を防ぐ方法
Hosgood et al. Cold ischaemic injury in kidney transplantation
RU2808054C2 (ru) Обработка органов ex vivo молекулами пэг-фосфолипида
WO2012030949A2 (en) B2-glycoprotein i peptide inhibitors
JP6515429B2 (ja) 人工血管、および、人工血管の製造方法
Xing et al. Liver regeneration: Influence-factors and mechanism of mesenchymal stem cell transplantation
JP2018519359A5 (enExample)
Lledó-Garcia et al. Optimizing outcomes by preconditioning the donor
Absaieri et al. Abo-Auda W, Benza RL. Therapeutic angiogenesis: review of current concepts and future directions. 2003; 22: 370-82 Abo-Auda W, Benza RL. Transmyocardial and percutane-ous myocardial revascularization: current concepts and
Wang Strategies for Prevention of Antibody Mediated Allograft Rejection